The Agreement Signed By Ranbaxy Laboratory

On April 7, 2014, Sun Pharmaceutical, based in India, and Daiichi Sankyo, based in Japan, jointly announced the sale of all 63.4% of Daiichi Sankyo`s 63.4% Ranbaxy to Sun Pharmaceutical for $4 billion. Under these agreements, Ranbaxy shareholders are expected to receive a 0.8 stake in Sun Pharmaceutical for each Ranbaxy share. [3] As a result of this acquisition, partner Daiichi-Sankyo is expected to hold a 9% interest in Sun Pharmaceutical. [16] (Reuters) – Indian generic drug maker Ranbaxy Laboratories Ltd pleaded guilty on Monday to drug safety charges and will pay $500 million in civil and criminal fines under the settlement agreement with the U.S. Department of Justice. However, the Attorney General stated that he had not seen any anti-competitive effects during his investigation as a result of the agreement. While Indian Ranbaxy, majority owned by Japan`s Daiichi Sankyo Co Ltd, finally got FDA approval in time, the agreement remained in place and could have been used to protect other drugs from both companies. The transaction ends a review of an agreement signed by the companies in 2010 to sell a generic version of Pfizer Inc.`s cholesterol-lowering drug Lipitor in the United States, without questioning each other`s exclusivity rights to other generic drugs. Ranbaxy Pharmaceuticals Inc (RPI), a wholly-adging subsidiary of Ranbaxy Laboratories Limited (RLL), announced today that it has entered into a licensing agreement with Alembic Pharmaceuticals Limited to exclusively market Desvenlafaxine-type basic outlet tablets in the U.S. healthcare system.

Alembic Pharmaceuticals Limited is a sponsor and manufacturer of the New Drug Application (NDA) Desvenlafaxine Base Extended Release Tablets. The product is a bioequivalent version of Pfizer Inc.`s innovative drug Pristiq®. Pristiq® market size is $590 million (IMS – MAT January 2013). “Ranbaxy… also believes that the agreement was pro-competitive and that it was an important part of the timely availability of the product for patients and the U.S. healthcare system,” a Ranbaxy spokesman said in an email to Reuters.